10-QPeriod: Q3 FY2006

3M CO Quarterly Report for Q3 Ended Sep 30, 2006

Filed October 27, 2006For Securities:MMM

Summary

3M Company's third quarter 2006 report shows solid top-line growth driven by both volume and acquisitions, with net sales increasing by 8.8% year-over-year to $5.858 billion. Net income rose to $894 million, or $1.18 per diluted share, up from $840 million, or $1.08 per diluted share, in the prior year's third quarter. This growth reflects continued demand across most of its business segments, with notable strength in Safety, Security and Protection Services, and Industrial and Transportation. However, operating income margins saw a slight contraction to 22.9% from 23.5%, primarily impacted by higher stock-based compensation expenses due to the adoption of SFAS No. 123R and certain transition costs related to the exploration of strategic alternatives for its branded pharmaceuticals business. The company also saw an increase in interest expense due to higher short-term debt levels supporting its aggressive share repurchase program. Despite these pressures, 3M's financial condition remains robust, supported by strong operating cash flows and a healthy balance sheet, with significant capital being returned to shareholders through dividends and share repurchases.

Key Highlights

  • 1Net sales increased by 8.8% to $5.858 billion for the third quarter of 2006 compared to the same period in 2005.
  • 2Net income grew to $894 million ($1.18 per diluted share) from $840 million ($1.08 per diluted share) in the prior year's quarter.
  • 3Operating income increased by 5.9% to $1.342 billion, though operating margins slightly compressed to 22.9% from 23.5%.
  • 4Stock-based compensation expense increased significantly due to the adoption of SFAS No. 123R, impacting operating income.
  • 5The company is actively pursuing strategic alternatives for its branded pharmaceuticals business, incurring associated costs.
  • 6Cash flow from operations decreased due to higher tax payments but remains strong at $2.517 billion for the nine months.
  • 73M continued its commitment to returning capital to shareholders, authorizing an additional $1 billion in share repurchases and increasing its dividend for the 48th consecutive year.

Frequently Asked Questions

The 8.8% increase in net sales to $5.858 billion was driven by a combination of factors. Local-currency sales grew by 7.3% due to a 6.5% increase in organic volume and a 1.7% contribution from acquisitions. Selling prices saw a slight decrease of 0.9%, while foreign currency translation added 1.5% to the overall sales growth.

Operating income margins narrowed to 22.9% from 23.5% year-over-year. This was primarily influenced by an increase in stock-based compensation expenses, a result of adopting SFAS No. 123R which mandates expensing stock options, and additional costs related to the strategic review of the company's branded pharmaceuticals business.

3M maintains strong liquidity, funded by ongoing operating cash flows. Net debt increased due to increased short-term debt supporting share repurchases, but the debt-to-total capital ratio remained healthy at 26%. The company has access to capital markets and continued to return value to shareholders through significant share repurchases and a 48th consecutive annual dividend increase.

The adoption of SFAS No. 123R (Share-Based Payment) effective January 1, 2006, requires 3M to expense stock-based compensation at fair value. This led to a notable increase in stock-based compensation expenses, impacting operating income and earnings per share compared to prior periods that used a different accounting method. The company also changed its approach to recognizing expense for retirement-eligible employees, further influencing the expense recognition pattern.